Which has higher earnings and valuation, NKTX or PDSB?

Nkarta is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is NKTX or PDSB more profitable?

Nkarta's return on equity of -30.90% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% PDS Biotechnology N/A -346.02% -102.36%

Do analysts recommend CNTN or PDSB?

PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 944.08%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, CNTN or PDSB?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is CNTN or PDSB more profitable?

Hillstream Biopharma's return on equity of -31.50% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% PDS Biotechnology N/A -346.02% -102.36%

Is WHWK or PDSB more profitable?

Whitehawk Therapeutics' return on equity of -79.63% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% PDS Biotechnology N/A -346.02% -102.36%

PDS Biotechnology (PDSB) Competitors

$0.86 -0.02 (-1.94%)

As of 01:57 PM Eastern

Compare

PDSB vs. NKTX, LFCR, CNTN, WHWK, and KPTI

Should you buy PDS Biotechnology stock or one of its competitors? MarketBeat compares PDS Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PDS Biotechnology include Nkarta (NKTX), Lifecore Biomedical (LFCR), Hillstream Biopharma (CNTN), Whitehawk Therapeutics (WHWK), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry.

How does PDS Biotechnology compare to Nkarta?

Nkarta (NASDAQ:NKTX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Nkarta is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

In the previous week, Nkarta had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Nkarta and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat Nkarta's score of 0.94 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Nkarta	Positive
PDS Biotechnology	Very Positive

Nkarta currently has a consensus target price of $10.75, indicating a potential upside of 275.22%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 944.08%. Given PDS Biotechnology's higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Nkarta has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nkarta's return on equity of -30.90% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
PDS Biotechnology	N/A	-346.02%	-102.36%

Summary

Nkarta beats PDS Biotechnology on 8 of the 14 factors compared between the two stocks.

How does PDS Biotechnology compare to Lifecore Biomedical?

PDS Biotechnology (NASDAQ:PDSB) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

PDS Biotechnology has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. PDS Biotechnology's return on equity of -346.02% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

In the previous week, Lifecore Biomedical had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Lifecore Biomedical and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat Lifecore Biomedical's score of 1.32 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Very Positive
Lifecore Biomedical	Positive

PDS Biotechnology has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Lifecore Biomedical	$128.87M	1.57	-$35.26M	-$0.94	N/A

PDS Biotechnology presently has a consensus price target of $9.00, suggesting a potential upside of 944.08%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 20.82%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, equities research analysts clearly believe PDS Biotechnology is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PDS Biotechnology has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Summary

PDS Biotechnology beats Lifecore Biomedical on 10 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Hillstream Biopharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Hillstream Biopharma's return on equity of -31.50% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
PDS Biotechnology	N/A	-346.02%	-102.36%

In the previous week, Hillstream Biopharma had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Hillstream Biopharma and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat Hillstream Biopharma's score of 0.63 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Hillstream Biopharma	Positive
PDS Biotechnology	Very Positive

PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 944.08%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Hillstream Biopharma is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

PDS Biotechnology beats Hillstream Biopharma on 10 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Whitehawk Therapeutics' return on equity of -79.63% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
PDS Biotechnology	N/A	-346.02%	-102.36%

Whitehawk Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Whitehawk Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 77.03%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 944.08%. Given PDS Biotechnology's higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Whitehawk Therapeutics has higher revenue and earnings than PDS Biotechnology. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	31.30	-$20.60M	-$1.68	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

In the previous week, Whitehawk Therapeutics had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 3 mentions for Whitehawk Therapeutics and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat Whitehawk Therapeutics' score of 0.96 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Whitehawk Therapeutics	Positive
PDS Biotechnology	Very Positive

Summary

Whitehawk Therapeutics beats PDS Biotechnology on 9 of the 14 factors compared between the two stocks.

How does PDS Biotechnology compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Karyopharm Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat Karyopharm Therapeutics' score of 0.94 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Karyopharm Therapeutics	Positive
PDS Biotechnology	Very Positive

PDS Biotechnology has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
PDS Biotechnology	N/A	-346.02%	-102.36%

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Karyopharm Therapeutics currently has a consensus price target of $17.17, indicating a potential upside of 80.32%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 944.08%. Given PDS Biotechnology's higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology has lower revenue, but higher earnings than Karyopharm Therapeutics. PDS Biotechnology is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.48	-$196.04M	-$15.09	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Summary

Karyopharm Therapeutics and PDS Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$48.12M	$3.65B	$6.79B	$12.57B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.29	21.44	27.46	25.42
Price / Sales	N/A	343.75	540.28	103.41
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	4.79	8.67	10.94	6.65
Net Income	-$34.50M	$23.87M	$3.57B	$336.83M
7 Day Performance	-1.35%	3.58%	2.71%	3.02%
1 Month Performance	-24.39%	3.61%	1.82%	0.62%
1 Year Performance	-29.34%	67.03%	36.26%	30.39%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	3.7399 of 5 stars	$0.86 -1.9%	$9.00 +941.7%	-33.8%	$48.28M	N/A	N/A	20	Positive News
NKTX Nkarta	4.0328 of 5 stars	$2.98 +6.6%	$10.75 +261.3%	+70.5%	$213.98M	N/A	N/A	140
LFCR Lifecore Biomedical	1.588 of 5 stars	$5.68 +2.7%	$6.50 +14.5%	-35.3%	$211.37M	$128.87M	N/A	690	News Coverage Positive News
CNTN Hillstream Biopharma	0.3678 of 5 stars	$3.03 -5.6%	N/A	N/A	$211.11M	N/A	N/A	2	Gap Down
WHWK Whitehawk Therapeutics	3.1794 of 5 stars	$4.23 -5.1%	$7.33 +73.3%	+144.9%	$209.92M	$7.14M	N/A	21	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. NKTX, LFCR, CNTN, WHWK, and KPTI

How does PDS Biotechnology compare to Nkarta?

Summary

How does PDS Biotechnology compare to Lifecore Biomedical?

Summary

How does PDS Biotechnology compare to Hillstream Biopharma?

Summary

How does PDS Biotechnology compare to Whitehawk Therapeutics?

Summary

How does PDS Biotechnology compare to Karyopharm Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. NKTX, LFCR, CNTN, WHWK, and KPTI

How does PDS Biotechnology compare to Nkarta?

Which has higher earnings and valuation, NKTX or PDSB?

Does the media favor NKTX or PDSB?

Do analysts prefer NKTX or PDSB?

Which has more risk & volatility, NKTX or PDSB?

Do insiders & institutionals believe in NKTX or PDSB?

Is NKTX or PDSB more profitable?

Summary

How does PDS Biotechnology compare to Lifecore Biomedical?

Is PDSB or LFCR more profitable?

Does the media prefer PDSB or LFCR?

Which has stronger earnings and valuation, PDSB or LFCR?

Do analysts recommend PDSB or LFCR?

Do institutionals & insiders believe in PDSB or LFCR?

Which has more volatility & risk, PDSB or LFCR?

Summary

How does PDS Biotechnology compare to Hillstream Biopharma?

Which has more risk and volatility, CNTN or PDSB?

Is CNTN or PDSB more profitable?

Does the media favor CNTN or PDSB?

Do analysts recommend CNTN or PDSB?

Which has stronger valuation & earnings, CNTN or PDSB?

Do insiders & institutionals believe in CNTN or PDSB?

Summary

How does PDS Biotechnology compare to Whitehawk Therapeutics?

Is WHWK or PDSB more profitable?

Which has more volatility and risk, WHWK or PDSB?

Do insiders & institutionals hold more shares of WHWK or PDSB?

Do analysts rate WHWK or PDSB?

Which has preferable earnings & valuation, WHWK or PDSB?

Does the media prefer WHWK or PDSB?

Summary

How does PDS Biotechnology compare to Karyopharm Therapeutics?

Which has more volatility & risk, KPTI or PDSB?

Does the media favor KPTI or PDSB?

Is KPTI or PDSB more profitable?

Do institutionals & insiders have more ownership in KPTI or PDSB?

Do analysts rate KPTI or PDSB?

Which has better valuation and earnings, KPTI or PDSB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools